Article
Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.
Journal of immunology research - 1 Jan 2014
Zimmermann Heiner, Weiland Theresa, Nourse Jamie P, Gandhi Maher K, Reinke Petra, Neuhaus Ruth, Karbasiyan Mohsen, Gärtner Barbara, Anagnostopoulos Ioannis, Riess Hanno, Trappe Ralf U, Oertel Stephan
Abstract excerpt
We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy. Previous reports had indicated that the lower affinity F allele affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and is linked to inferior outcome of rituximab monotherapy in B cell malignancies. 25 patients with PTLD after solid organ...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.